Sulforaphane mitigates genotoxicity induced by radiation and anticancer drugs in human lymphocytes

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 758, Issue 1-2, 2013, Pages 29-34

  Katoch, Omika ^a   Kumar, Arun ^a   Adhikari, Jawahar S ^a   Dwarakanath, Bilikere S ^a   Agrawala, Paban K ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

HDAC inhibitor; Micronucleus; Radiation protection; Sulforaphane

Indexed keywords

BLEOMYCIN; CD34 ANTIGEN; DOXORUBICIN; HISTONE DEACETYLASE; HISTONE H4; SULFORAPHANE;

ADULT; ARTICLE; BETA RADIATION; BLOOD CULTURE; CELL POPULATION; CONTROLLED STUDY; DNA REPAIR; DNA STRAND BREAKAGE; ENZYME ACTIVITY; FEMALE; GAMMA RADIATION; GENOTOXICITY; HISTONE ACETYLATION; HUMAN; IN VITRO STUDY; LYMPHOCYTE; MALE; MICRONUCLEUS; NORMAL HUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; STIMULATION;

BRASSICA OLERACEA VAR. ITALICA;

EID: 84888010939     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2013.08.009     Document Type: Article

References (24)

1. Brizel D.M., Wasserman T.H., Henke M., Strnad V., Rudat V., Monnier A., Eschwege F., Zhang J., Russell L., Oster W., Sauer R. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. 2000, 18:3339-3345.
2. Weiss J.F., Landauer M.R. History and development of radiation-protective agents. Int. J. Radiat. Biol. 2009, 85:539-573.
3. Licciardi P.V., Kwa F.A., Ververis K., Di Costanzo N., Balcerczyk A., Tang M.L., El-Osta A., Karagiannis T.C. Influence of natural and synthetic histone deacetylase inhibitors on chromatin. Antioxid. Redox Signal. 2012, 17:340-354.
4. Seidel C., Schnekenburger M., Dicato M., Diederich M. Histone deacetylase modulators provided by mother nature. Genes Nutr. 2012, 7:357-367.
5. Chung Y.L., Wang A.J., Yao L.F. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy. Mol. Cancer Ther. 2004, 3:317-325.
6. Benedict A.L., Knatko E.V., Dinkova-Kostova A.T. The indirect antioxidant sulforaphane protects against thiopurine-mediated photooxidative stress. Carcinogenesis 2012, 33:2457-2466.
7. Keum Y.S. Regulation of the Keap1/Nrf2 system by chemopreventive sulforaphane: implications of posttranslational modifications. Ann. N. Y. Acad. Sci. 2011, 1229:184-189.
8. Sharma D.C. Delhi radiation leak exposes lax safety procedures. Lancet Oncol. 2010, 11:518.
9. Dey A.B., Mohanan S., Damodaran D., Soneja M., Jain N., Mohan A., Vikram N.K., Sood R. Radiation accident at Mayapuri scrap market, Delhi, 2010. Radiat. Prot. Dosimetry 2012, 151:645-651.
10. Kuo Y.C., Yang N.S., Chou C.J., Lin L.C., Tsai W.J. Regulation of cell proliferation, gene expression, production of cytokines, and cell cycle progression in primary human t lymphocytes by piperlactam s isolated from Piper kadsura. Mol. Pharmacol. 2000, 58:1057-1066.
11. Mahabir A.G., Schaap M.M., Pennings J.L.A., Benthem J.V., Hendriksen C.F.M., Steeg H.V. Comparison of clastogen-induced gene expression profiles in wild-type and DNA repair-deficient Rad54/Rad54B cells. BMC Genom. 2010, 11:24.
12. Yue J., Lan S., Yuan C., Shen Z. Prognostic values of filamin-a status for topoisomerase ii poison chemotherapy. Int. J. Biol. Sci. 2012, 8:442-450.
13. Fenech M. Cytokinesis blocked micronucleus cytome assay. Nat. Prot. 2007, 2:1084-1104.
14. Floratou K., Giannopoulou E., Antonacopoulou A., Karakantza M., Adonakis G., Kardamakis D., Matsouka P. Oxidative stress due to radiation in CD34(+) hematopoietic progenitor cells: protection by IGF-1. J. Radiat. Res. 2012, 53:672-685.
15. Morse M.A., Stoner G.D. Cancer chemoprevention: principles and prospects. Carcinogenesis 1993, 14:1737-1746.
16. Kada T., Inoue T., Namiki N. Environmental desmutagens and antimutagens. Environmental Mutagenesis and Plant Biology 1982, 137-151. Praeger, New York, NJ. E.J. Klekowski (Ed.).
17. Ramel C., Alekperov U.K., Ames B.N., Kada T., Wattenberg L.W. Inhibitors of mutagenesis and their relevance to carcinogenesis. Mutat. Res. 1986, 168:47-65.
18. De Flora S., Ramel C. Mechanisms of inhibitors of mutagenesis and carcinogenesis. Classification and overview. Mutat. Res. 1988, 202:285-306.
19. Fimognari C., Berti F., Cantelli-Forti G., Hrelia P. Effect of sulforaphane on micronucleus induction in cultured human lymphocytes by four different mutagens. Environ. Mol. Mutagen. 2005, 46:260-267.
20. Young-Sam K. Regulation of the Keap1/Nrf2 system by chemopreventive sulforaphane: implications of posttranslational modifications. Ann. N.Y. Acad. Sci. 2011, 1229:184-189.
21. Ho E., Clarke J.D., Dashwood R.H. dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J. Nutr. 2009, 139:2393-2396.
22. Katoch O., Dwarakanath B.S., Agrawala P.K. HDAC inhibitors: applications in oncology and beyond. HOAJ Biol. 2013, 4:2. 10.7243/2050-0874-2-2.
23. Sharma G.G., So S., Gupta A., Kumar R., Cayrou C., Avvakumov N., Bhadra U., Pandita R.K., Porteus M.H., Chen D.J., Cote J., Pandita T.K. MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol. Cell Biol. 2010, 30:3582-3595.
24. Hsiao K.Y., Mizzen C.A. Histone H4 deacetylation facilitates 53BP1 DNA damage signaling and double-strand break repair. J. Mol. Cell Biol. 2013, 5:157-165.